Owing to various reasons, such as growing manufacturing demand, need for specialized facilities, equipment and operational expertise, and high costs of development associated with certain drugs / therapies, a number of ophthalmic drug developers have demonstrated a preference to outsource certain aspects of drug development and production operations to contract service providers.
To order this 375+ page report, which features 180+ figures and 195+ tables, please visit this – https://www.rootsanalysis.com/reports/view_document/ophthalmic-drugs-cmo/294.html
The USD 1.7 billion financial opportunity (by 2030) within the ophthalmic drugs contract manufacturing market has been analyzed across the following segments:
- Type of product
- Ophthalmic API
- Ophthalmic drug FDF
- Type of FDF manufactured
- Solid
- Semi-solid
- Liquid / suspension
- Type of primary packaging
- Ampoule / vial
- Glass / plastic bottle
- Ointment tube
- Blister packing
- Other forms
- Scale of manufacturing
- Clinical
- Commercial
- Company size
- Small
- Mid-sized
- Large
- Very large
- Target disease indication
- Age-related macular degeneration
- Dry eye
- Glaucoma
- Other disease segments
- Key geographical regions
- North America (US, Canada and Mexico)
- Europe (UK, Germany, France, Spain, Italy and rest of Europe)
- Asia-Pacific (India, China, Japan, Australia and rest of Asia-Pacific)
- Rest of the world
The Ophthalmic Drugs Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms (Ophthalmic Drops, Emulsions, Gels, Injections, Lotions, Ointments, Suspensions, and Tablets / Capsules), 2020-2030.” report features the following companies, which we identified to be key players in this domain:
- Akorn
- Akums
- Bal Pharma
- Catalent
- Cayman Chemical
- Entod Pharmaceuticals
- Farmigea
- Glenmark Pharmaceuticals
- Indiana Ophthalmics
- Lomapharm
- Medichem
- Pillar5 Pharma
- Recipharm
- Salvat
- Sterling Pharmaceutical Services
- Sunways India
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Current Market Landscape
5. Company Competitiveness Analysis
6. Ophthalmic Drugs Contract Manufacturing in North America: Company Profiles
7. Ophthalmic Drugs Contract Manufacturing in Europe: Company Profiles
8. Ophthalmic Drugs Contract Manufacturing in Asia-Pacific: Company Profiles
9. Clinical Trial Analysis
10. Capacity Analysis
11. Demand Analysis
12. Market Forecast
13. Case Study: Comparison of Small Molecule and Large Molecule Ophthalmic Drugs / Therapies
14. SWOT Analysis
15. Survey Analysis
16. Executive Insights
17. Future Growth Opportunities
18. Appendix 1: List of Ophthalmic Medical Device Contract Manufacturers
19. Appendix 2: Tabulated Data
20. Appendix 3: List of Companies and Organizations
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/ophthalmic-drugs-cmo/294.html
Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091Gaurav.Chaudhary@rootsanalysis.com
0 responses on "More than 240 companies across the globe claim to have the required capabilities to offer variety of services on a contract basis"